Dateline City:
KENILWORTH, N.J.
Acquisition Expands Mercks Oncology Portfolio with Novel Oral BET Inhibitor, OTX015
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that it has acquired, through a subsidiary, OncoEthix, a
Swiss-based privately held biotechnology company specializing in
oncology drug development. Through the acquisition, Merck has gained an
investigational, novel oral BET (bromodomain) inhibitor, OTX015, which
is currently in Phase 1b studies for the treatment of hematological
malignancies and advanced solid tumors.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more